Keywords
Last Name
Institution

Takao Ohnuma

TitlePROFESSOR
InstitutionMount Sinai
DepartmentHematology and Medical Oncology
Address1470 Madison Avenue
3rd floor
New York NY 10029
Phone212-241-6756
    Other Positions
    TitlePROFESSOR
    InstitutionMount Sinai
    DepartmentOncological Sciences


     Bibliographic 
     selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Ohnuma T, Lehrer D, Ren C, Cho SY, Maniar M, Silverman L, Sung M, Gretz HF, Benisovich V, Navada S, Akahoho E, Wilck E, Taft DR, Roboz J, Wilhelm F, Holland JF. Phase 1 study of intravenous rigosertib (ON 01910.Na), a novel benzyl styryl sulfone structure producing G2/M arrest and apoptosis, in adult patients with advanced cancer. Am J Cancer Res. 2013; 3(3):323-38.
      View in: PubMed
    2. Oussenko IA, Holland JF, Reddy EP, Ohnuma T. Effect of ON 01910.Na, an anticancer mitotic inhibitor, on cell-cycle progression correlates with RanGAP1 hyperphosphorylation. Cancer Res. 2011 Jul 15; 71(14):4968-76.
      View in: PubMed
    3. Cho SY, Ohnuma T, Silverman LR, Holland JF, Roboz J. Discontinuous drug binding to proteins: binding of an antineoplastic benzyl styryl sulfone to albumin and enzymes in vitro and in phase I clinical trials. Drug Metab Dispos. 2010 Sep; 38(9):1480-5.
      View in: PubMed
    4. Xu D, Wang F, Ohnuma T, Jin L. [Adenovirus-mediated transfer of anti-MDR1 ribozyme in the treatment of multidrug-resistant human lymphoma in SCID mice]. Zhonghua Zhong Liu Za Zhi. 2002 Nov; 24(6):529-32.
      View in: PubMed
    5. Halatsch ME, Schmidt U, Bötefür IC, Holland JF, Ohnuma T. Overexpression of deletion-mutant epidermal growth factor receptor is associated with altered genotoxic stress-provoked p53 mRNA induction in a human glioblastoma cell line. Anticancer Res. 2001 Jan-Feb; 21(1A):189-95.
      View in: PubMed
    6. Halatsch ME, Schmidt U, Bötefür IC, Holland JF, Ohnuma T. Marked inhibition of glioblastoma target cell tumorigenicity in vitro by retrovirus-mediated transfer of a hairpin ribozyme against deletion-mutant epidermal growth factor receptor messenger RNA. J Neurosurg. 2000 Feb; 92(2):297-305.
      View in: PubMed
    7. Ohnuma T, Kobayashi H, Wang FS. Anti-MDR1 Ribozyme Gene Therapy. Methods Mol Med. 2000; 35:207-45.
      View in: PubMed
    8. Wang FS, Kobayashi H, Liang KW, Holland JF, Ohnuma T. Retrovirus-mediated transfer of anti-MDR1 ribozymes fully restores chemosensitivity of P-glycoprotein-expressing human lymphoma cells. Hum Gene Ther. 1999 May 1; 10(7):1185-95.
      View in: PubMed
    9. Kobayashi H, Takemura Y, Holland JF, Ohnuma T. Vincristine saturation of cellular binding sites and its cytotoxic activity in human lymphoblastic leukemia cells: mechanism of inoculum effect. Biochem Pharmacol. 1998 Apr 15; 55(8):1229-34.
      View in: PubMed
    10. Yokoyama Y, Ito T, Hanson V, Schwartz GK, Aderem AA, Holland JF, Tamaya T, Ohnuma T. PMA-induced reduction in invasiveness is associated with hyperphosphorylation of MARCKS and talin in invasive bladder cancer cells. Int J Cancer. 1998 Mar 2; 75(5):774-9.
      View in: PubMed
    11. Masuda Y, Kobayashi H, Holland JF, Ohnuma T. Reversal of multidrug resistance by a liposome-MDR1 ribozyme complex. Cancer Chemother Pharmacol. 1998; 42(1):9-16.
      View in: PubMed
    12. Dorai T, Kobayashi H, Holland JF, Ohnuma T. Modulation of platelet-derived growth factor-beta mRNA expression and cell growth in a human mesothelioma cell line by a hammerhead ribozyme. Mol Pharmacol. 1994 Sep; 46(3):437-44.
      View in: PubMed
    13. Kobayashi H, Kim N, Halatsch ME, Ohnuma T. Specificity of ribozyme designed for mutated DHFR mRNA. Biochem Pharmacol. 1994 Apr 29; 47(9):1607-13.
      View in: PubMed
    14. Kobayashi H, Dorai T, Holland JF, Ohnuma T. Reversal of drug sensitivity in multidrug-resistant tumor cells by an MDR1 (PGY1) ribozyme. Cancer Res. 1994 Mar 1; 54(5):1271-5.
      View in: PubMed
    15. Kobayashi H, Dorai T, Holland JF, Ohnuma T. Cleavage of human MDR1 mRNA by a hammerhead ribozyme. FEBS Lett. 1993 Mar 15; 319(1-2):71-4.
      View in: PubMed
    16. Fujii M, Ohnuma T, Szrajer L, Holland JF, Biller H, Okabe M. Effects of mitomycin-C and etoposide in cell culture and in nude mice: the role of G-CSF mutein. Cancer Invest. 1993; 11(3):283-90.
      View in: PubMed
    17. Takemura Y, Ohnuma T. N10-propargyl-5,8-dideazafolic acid (CB3717): inhibitory effects on human leukemia cell lines resistant to methotrexate or trimetrexate. Mt Sinai J Med. 1992 Oct; 59(5):419-24.
      View in: PubMed
    18. Kikuchi T, Ohnuma T, Holland JF, Spitler LE. Penetration of anti-melanoma immunotoxin into multicellular tumor spheroids and cell kill effects. Cancer Immunol Immunother. 1992; 35(5):302-6.
      View in: PubMed
    19. Kobayashi H, Takemura Y, Ohnuma T. Relationship between tumor cell density and drug concentration and the cytotoxic effects of doxorubicin or vincristine: mechanism of inoculum effects. Cancer Chemother Pharmacol. 1992; 31(1):6-10.
      View in: PubMed
    20. Schwartz GK, Arkin H, Holland JF, Ohnuma T. Protein kinase C activity and multidrug resistance in MOLT-3 human lymphoblastic leukemia cells resistant to trimetrexate. Cancer Res. 1991 Jan 1; 51(1):55-61.
      View in: PubMed
    21. Fountzilas G, Inoue S, Ohnuma T. Schedule-dependent interaction of cytarabine plus doxorubicin or cytarabine plus mitoxantrone in acute myelocytic leukemia cells in culture. Leukemia. 1990 May; 4(5):321-4.
      View in: PubMed
    22. Arkin H, Ohnuma T, Kamen BA, Holland JF, Vallabhajosula S. Multidrug resistance in a human leukemic cell line selected for resistance to trimetrexate. Cancer Res. 1989 Dec 1; 49(23):6556-61.
      View in: PubMed
    23. Sridhar KS, Ohnuma T, Nieburgs HE, Duncan RC, Holland JF. Relationship between the in vitro colony growth of human tumors and cytologic diagnosis. Cancer. 1989 Dec 1; 64(11):2275-8.
      View in: PubMed
    24. Inoue S, Ohnuma T. Effects of physiological oxygen environment on drug-induced cell lethality of multicellular tumor spheroids from human lung cancer. Sel Cancer Ther. 1989; 5(1):13-22.
      View in: PubMed
    25. Kohno N, Ohnuma T, Kaneko M, Holland JF. Interactions of doxorubicin and cis-platin in squamous carcinoma cells in culture. Br J Cancer. 1988 Sep; 58(3):330-4.
      View in: PubMed
    26. Kohno N, Ohnuma T, Biller HF, Holland JF. Effects of cisplatin plus fluorouracil vs cisplatin plus cytarabine on head and neck squamous multicellular tumor spheroids. Arch Otolaryngol Head Neck Surg. 1988 Feb; 114(2):157-61.
      View in: PubMed
    27. Kano Y, Ohnuma T, Okano T, Holland JF. Effects of vincristine in combination with methotrexate and other antitumor agents in human acute lymphoblastic leukemia cells in culture. Cancer Res. 1988 Jan 15; 48(2):351-6.
      View in: PubMed
    28. Inoue S, Ohnuma T, Takaoka K, Suzuki Y, Kaneko M, Safirstein R, Holland JF. Effects of doxorubicin and cisplatin on multicellular tumor spheroids from human lung cancer. Cancer Drug Deliv. 1987; 4(4):213-24.
      View in: PubMed
    29. Williams CK, Cuttner J, Ohnuma T, Ambinder EP, Ferreira PP, Holland JF. Iatrogenic and idiopathic acute myelogenous leukemia: a comparison of clinical features and treatment complications. Med Oncol Tumor Pharmacother. 1987; 4(2):59-66.
      View in: PubMed
    30. Kohno N, Ohnuma T, Holland JF, Biller H. Effects of anticancer agents on the shedding of cells from human multicellular tumor spheroids. Invasion Metastasis. 1987; 7(5):264-74.
      View in: PubMed
    Ohnuma's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts
    _
    Co-Authors
    _
    Similar People
    _
    Same Department
     
    Mount Sinai Profiles is managed by Conduits - The Institutes for Translational Sciences at Icahn School of Medicine, supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences of the National Institutes of Health through Grant Number UL1TR000067